SCHEMBL18405689

SCHEMBL18405689

COC(=O)/C=C/C(=O)OCC(C)NS(=O)(=O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ ALDH1A1 P00352 4/20 0.49
▸ CYP1A2 P05177 3/20 0.49
▸ CYP2C9 P11712 3/20 0.49
▸ CYP2C19 P33261 3/20 0.49
▸ POLB P06746 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ HPGD P15428 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ ADAMTS4 O75173 3/20 0.43
▸ MMP9 P14780 2/20 0.41
▸ MMP2 P08253 2/20 0.41
▸ MMP3 P08254 2/20 0.41
▸ MMP13 P45452 2/20 0.41
▸ MMP1 P03956 1/20 0.41
▸ MMP7 P09237 1/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ SLC1A3 P43003 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18406868 0.96 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL18406862 0.96 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL18405674 0.91 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL18405676 0.90 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL18405685 0.86 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL18406885 0.84 ADAMTS4 (0.53) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL18406893 0.84 ADAMTS4 (0.53) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL18405738 0.84 CTSL (0.59) ALDH1A1ADAMTS4MMP9MMP2
SCHEMBL18405666 0.82 MEN1 (0.51) ALDH1A1HPGDHSD17B10MMP9MMP2
SCHEMBL18406895 0.80 ALDH1A1 (0.49) ALDH1A1CYP1A2CYP2C9CYP2C19MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170020837-A1 FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE Nguyen, Mark Quang (US) 2017-01-26 — — US disclosed
US-20170020837-A1 FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE Nguyen, Mark Quang (US) 2017-01-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170020837-A1 FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE FH, FPGS, APC SMN1; SMN2 79/4885ALDH1A1 1949/4885CYP1A2 1195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback